# CREATE: Cross-tumoral Phase 2 With Crizotinib

> **NCT01524926** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 582 (estimated)

## Conditions studied

- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
- Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
- Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1
- Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Locally Advanced and/or Metastatic Clear Cell Sarcoma
- Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma

## Interventions

- **DRUG:** Crizotinib (PF-02341066)

## Key facts

- **NCT ID:** NCT01524926
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2017-12-06
- **Final completion:** 2022-10-30
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524926, "CREATE: Cross-tumoral Phase 2 With Crizotinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01524926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*